Hikma Continues To Mull Potential To Go Alone On Xyrem
Royalties Due To Jazz One Factor For Hikma; ‘Balance What Works Best For Us’
Hikma’s recently installed CEO Riad Mishlawi told a packed room at the recent Jefferies 2024 London Healthcare Conference that Hikma had not reached a decision on pursuing its Xyrem ANDA product.
You may also be interested in...
Lupin may enjoy 180 days of market exclusivity for its proposed generic to Jazz’s next-generation Xywav treatment for sleep disorders.
After a tough 2022 for its generics business, Hikma is predicting big things for the division this year, raising its full-year guidance from 20% growth to nearly 30% as new CEO Riad Mishlawi prepares to take the reins from the start of September. Meanwhile, the firm has also picked up assets from Akorn following its collapse.
Hikma has begun 2023 with the long-awaited launch of a US authorized generic version of Xyrem (sodium oxybate). Meanwhile, the company has also struck a deal with Junshi Biosciences for toripalimab in the MENA region.